KR20180032689A - 인플루엔자를 치료하기 위한 화합물 및 방법 - Google Patents

인플루엔자를 치료하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20180032689A
KR20180032689A KR1020187008142A KR20187008142A KR20180032689A KR 20180032689 A KR20180032689 A KR 20180032689A KR 1020187008142 A KR1020187008142 A KR 1020187008142A KR 20187008142 A KR20187008142 A KR 20187008142A KR 20180032689 A KR20180032689 A KR 20180032689A
Authority
KR
South Korea
Prior art keywords
influenza
group
pharmaceutical composition
term
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187008142A
Other languages
English (en)
Korean (ko)
Inventor
진-프란코이스 로시그놀
제이. 에드워드 셈플
Original Assignee
로마크 레버러토리즈, 엘.씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180032689(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 로마크 레버러토리즈, 엘.씨. filed Critical 로마크 레버러토리즈, 엘.씨.
Publication of KR20180032689A publication Critical patent/KR20180032689A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H01L31/125—
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F55/00—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto
    • H10F55/18—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto wherein the radiation-sensitive semiconductor devices and the electric light source share a common body having dual-functionality of light emission and light detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Composite Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020187008142A 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법 Ceased KR20180032689A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22089109P 2009-06-26 2009-06-26
US61/220,891 2009-06-26
PCT/US2010/039638 WO2010151577A1 (en) 2009-06-26 2010-06-23 Compounds and methods for treating influenza

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177036332A Division KR20170141830A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030422A Division KR20190120436A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법

Publications (1)

Publication Number Publication Date
KR20180032689A true KR20180032689A (ko) 2018-03-30

Family

ID=43381033

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187008142A Ceased KR20180032689A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법
KR1020197030422A Ceased KR20190120436A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법
KR1020177036332A Withdrawn KR20170141830A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법
KR1020127001505A Expired - Fee Related KR101812054B1 (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197030422A Ceased KR20190120436A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법
KR1020177036332A Withdrawn KR20170141830A (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법
KR1020127001505A Expired - Fee Related KR101812054B1 (ko) 2009-06-26 2010-06-23 인플루엔자를 치료하기 위한 화합물 및 방법

Country Status (16)

Country Link
US (6) US9023877B2 (enExample)
EP (2) EP2445349B1 (enExample)
JP (3) JP5932640B2 (enExample)
KR (4) KR20180032689A (enExample)
CN (2) CN102480967A (enExample)
AP (1) AP2012006064A0 (enExample)
AU (2) AU2010264479B2 (enExample)
BR (2) BRPI1014322A2 (enExample)
CA (3) CA2766642C (enExample)
EA (1) EA030679B1 (enExample)
ES (1) ES2914949T3 (enExample)
HK (1) HK1255283A1 (enExample)
MX (2) MX391013B (enExample)
PT (1) PT2445349T (enExample)
WO (1) WO2010151577A1 (enExample)
ZA (1) ZA201200263B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) * 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
AU2016201747B2 (en) * 2011-05-16 2017-06-01 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
CN107096032A (zh) * 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US10131643B2 (en) 2013-07-04 2018-11-20 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Tizoxanide carbamate and pharmaceutical use thereof
CN104771398B (zh) * 2014-01-09 2017-01-18 湖南大学 N‑[5‑（2‑硝基乙基）噻唑‑2‑基]苯甲酰胺及其医药用途
JP6633092B2 (ja) * 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
HK1250945A1 (zh) * 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
CN107286149B (zh) * 2017-05-10 2021-02-12 南华大学 N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用
CN107141267B (zh) * 2017-06-22 2019-04-09 湖南大学 N-(5-酰基噻唑-2-基)酰胺及其制备方法与应用
CN107235927B (zh) * 2017-06-22 2019-04-16 湖南大学 N-(5-酰基噻唑-2-基)哌嗪基酰胺及其医药用途
KR102077833B1 (ko) * 2018-12-10 2020-02-14 류형준 기능성 식품조성물
WO2020227004A1 (en) * 2019-05-03 2020-11-12 President And Fellows Of Harvard College Combination therapy for treating influenza virus infection
WO2021046446A1 (en) * 2019-09-06 2021-03-11 Yourchoice Therapeutics, Inc. Compositions and methods of use for enhancing fertility
CN118978524A (zh) * 2019-09-11 2024-11-19 绍兴君科臻元医药科技有限公司 硝唑尼特衍生物及其医药用途
JP2023512622A (ja) * 2020-01-21 2023-03-28 アカデミー オブ ミリタリー メディカル サイエンシズ ニタゾキサニド及びその活性型であるチゾキサニドのＳＡＲＳ－ＣｏＶ－２感染症の治療への適用
WO2021180251A1 (zh) * 2020-03-09 2021-09-16 北京强新生物科技有限公司 治疗冠状病毒感染的联用药物及治疗方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
RU2726070C1 (ru) * 2020-03-23 2020-07-08 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ патогенетической коррекции метаболических нарушений при инфекционном мононуклеозе, вызванном вирусом Эпштейна-Барр
WO2021202600A1 (en) * 2020-03-30 2021-10-07 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
WO2022109148A1 (en) * 2020-11-18 2022-05-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Small molecule inhibitors of sars-cov-2 infections
CN116456980A (zh) * 2021-03-29 2023-07-18 北京大学 噻唑类化合物在制备治疗和预防癌症药物中的用途
WO2022214855A1 (es) * 2021-04-10 2022-10-13 Siegfried Rhein, S.A. De C.V. Uso de nitazoxanida para la preparación de medicamento para prevenir o tratar infección causada por coronavirus sars-cov-2
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
CN113277994A (zh) * 2021-05-18 2021-08-20 杜心赟 噻唑类化合物及其制备方法和用途
CN116898846B (zh) * 2022-04-12 2025-10-24 成都贝诺科成生物科技有限公司 一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1177206A (en) 1967-11-28 1970-01-07 Pfizer & Co C Lung Antiviral Factor
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4343945A (en) 1979-01-23 1982-08-10 Olin Corporation 5-Benzamido-3-trichloromethyl-1,2,4-thiadiazoles and their use as herbicides, fungicides and insecticides
US4337081A (en) 1979-01-23 1982-06-29 Olin Corporation 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides
SU910628A1 (ru) 1980-04-22 1982-03-07 Гродненский государственный медицинский институт Способ получени 2-ациламинотиазолов
JPS56158703A (en) 1980-05-10 1981-12-07 Sankyo Co Ltd Fungicide
US4416683A (en) 1980-09-16 1983-11-22 Eli Lilly And Company Benzamides, compositions and agricultural method
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US5169846A (en) 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
PT740650E (pt) 1994-01-28 2004-10-29 Univ Kentucky Res Found Co-farmacos como um metodo de administracao controlada de farmacos
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
SI0755386T1 (en) * 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
SI20149B (en) 1997-05-07 2001-08-31 Romark Lab Lc Pharmaceutical compositions of tizoxanide and nitazoxanide
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
DE60208630T2 (de) 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
WO2002092584A1 (en) 2001-05-14 2002-11-21 Nihon Nohyaku Co., Ltd. Thiadiazole derivatives, pesticides for agricultural and horticultural use and usage thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003335680A (ja) 2002-05-21 2003-11-25 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
CA2488342A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
EP1658304A4 (en) * 2002-09-28 2009-01-14 Massachusetts Inst Technology THERAPY ANTIGRIPPALE
US6737382B1 (en) 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
US20050090506A1 (en) 2003-10-24 2005-04-28 Nippon Soda Co., Ltd. Insecticidal perfluoroalkylthiazole derivatives
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
ATE541844T1 (de) 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
BRPI0712720A2 (pt) 2006-05-31 2012-11-20 Abbott Lab compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos
PE20080401A1 (es) 2006-07-07 2008-06-23 Boehringer Ingelheim Int DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US8044075B2 (en) 2006-12-05 2011-10-25 Glaxosmithkline IL-8 receptor antagonists
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
CA2743723A1 (en) 2008-11-19 2010-05-27 Pauline C. Ting Inhibitors of diacylglycerol acyltransferase
AU2010226857B2 (en) * 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) * 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.

Also Published As

Publication number Publication date
WO2010151577A1 (en) 2010-12-29
US10912768B2 (en) 2021-02-09
EA030679B1 (ru) 2018-09-28
JP2017197552A (ja) 2017-11-02
KR20190120436A (ko) 2019-10-23
MX341877B (es) 2016-09-06
HK1255283A1 (zh) 2019-08-09
CA3038405C (en) 2022-02-01
KR101812054B1 (ko) 2017-12-27
ZA201200263B (en) 2012-09-26
EP2445349B1 (en) 2022-02-09
CN108042535A (zh) 2018-05-18
KR20120102570A (ko) 2012-09-18
EA201270077A1 (ru) 2012-12-28
CA2766642A1 (en) 2010-12-29
AU2010264479A1 (en) 2012-01-19
CA2968113C (en) 2019-05-14
MX391013B (es) 2025-03-21
US20160228415A1 (en) 2016-08-11
JP5932640B2 (ja) 2016-06-08
US9345690B2 (en) 2016-05-24
EP3895706A1 (en) 2021-10-20
ES2914949T3 (es) 2022-06-17
JP2012531420A (ja) 2012-12-10
EP2445349A1 (en) 2012-05-02
CN102480967A (zh) 2012-05-30
US20210177809A1 (en) 2021-06-17
MX2012000230A (es) 2012-01-25
BR122020003634B1 (pt) 2021-03-16
EP2445349A4 (en) 2012-12-05
US20150250768A1 (en) 2015-09-10
CA2968113A1 (en) 2010-12-29
US10363243B2 (en) 2019-07-30
US20190307730A1 (en) 2019-10-10
US20100330173A1 (en) 2010-12-30
JP2016172749A (ja) 2016-09-29
JP6464225B2 (ja) 2019-02-06
AU2017221828A1 (en) 2017-09-21
US9820975B2 (en) 2017-11-21
AU2010264479B2 (en) 2017-06-01
KR20170141830A (ko) 2017-12-26
CA3038405A1 (en) 2010-12-29
US9023877B2 (en) 2015-05-05
PT2445349T (pt) 2022-05-16
US20180078533A1 (en) 2018-03-22
BR122020003634B8 (pt) 2021-07-27
AP2012006064A0 (en) 2012-02-29
JP6188863B2 (ja) 2017-08-30
CA2766642C (en) 2017-09-05
BRPI1014322A2 (pt) 2015-08-25
US11850237B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
KR101812054B1 (ko) 인플루엔자를 치료하기 위한 화합물 및 방법
CN102803203B (zh) 卤代烷基杂芳基苯甲酰胺化合物
EP3881856B1 (en) Pharmaceutical composition for treating aplastic anemia
JP2013512222A (ja) シアロキメラ化合物
EP1740176A2 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
HK1171170A (en) Compounds and methods for treating influenza
Rajasekharan Milan Bonotto

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180322

Application number text: 1020177036332

Filing date: 20171218

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180820

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190318

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180820

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190318

Comment text: Decision to Refuse Application

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190717

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190617

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190318

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180820

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191016

Application number text: 1020177036332

Filing date: 20171218

PJ0201 Trial against decision of rejection

Patent event date: 20191016

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190717

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190318

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210203

Appeal identifier: 2019101003405

Request date: 20191016

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101003405; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191016

Effective date: 20210203

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210203

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20191016

Decision date: 20210203

Appeal identifier: 2019101003405

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210305

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20210305

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2019101003405

Request date: 20191016

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210203

WITB Written withdrawal of application